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Abstract 
Today, the combination of diabetes mellitus (DM), either Type 1 or Type 2, and hypertension 
(HTN) have led to an increase in micro and macro vascular damage resulting in enhanced 
development of cardiovascular disease, cerebral infarction, nephropathy, neuropathy, and 
retinopathy. Prolonged HTN in patients with diabetes  results in irreversible damage to the blood 
vessels which leads to early formation of atherosclerotic plaques that can dislodge causing a 
thromboembolic event. Tight control of blood pressure in patients with diabetes is required to 
prevent vascular remodeling; however, there remains some confusion regarding appropriate 
blood pressure parameters in patients with diabetes. Per the American Diabetes Association 
(ADA) 2017 Guidelines and Joint National Commission 2017 Hypertension Guidelines, the 
recommended goal blood pressure in patients with diabetes is a systolic blood pressure (SBP) 
less than 140 mm Hg and diastolic blood pressure (DBP) less than 90 mm Hg. However, 
depending on the person’s health history, comorbidities, and risk factors, more stringent control 
may need to be considered. Ultimately, with a blood pressure greater than 140/90, initiation of a 
pharmacological agent is required. However, the ideal antihypertensive agent to initiate remains 
challenging for clinicians and requires use of evidence-based data combined with patient risk 
factors to determine the best course of action. Therefore, setting appropriate parameters for blood 
pressure control, as well as selecting the appropriate treatment modality, is a primary goal of the 
primary care provider to manage and treat hypertension in patients with diabetes. 
 Keywords: diabetes, hypertension, management   
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The Management and Treatment of Hypertension in Patients with Diabetes 
Background 
 A pleasant 60-year-old female presented to the clinic for management and treatment of 
diabetes. She reported being diagnosed about two years ago and had been taking metformin 
twice a day. In addition to diabetes, she has a past medical history of hypertension and 
hyperlipidemia. Her last clinic visit was over a year ago and today she had elevated cholesterol 
and glycosylated hemoglobin (Hgb A1C) levels, as well as high blood pressure. Based on the 
data collected and the medical history, the patient was at risk for complications associated with 
hypertension and requires interventions, either pharmacological or non-pharmacological to 
control.  
In the patient with diabetes, elevated blood pressure can result in life threatening 
complications such as the development of microvascular and macro vascular disease. Quick 
identification and treatment of hypertension is crucial to maintaining health and wellness, 
especially in patients with diabetes, wherein tighter blood pressure control is required to prevent 
health risks. Already, the prevalence of hypertension in patients with diabetes today continues to 
result in substantial morbidity and mortality (Vijan, & Hayward, 2003). Therefore, 
understanding the risks and knowing the proper treatment course will prevent life altering 
conditions and promote quality of life. 
 The parameters for blood pressure control in patients with diabetes has been widely 
researched and, per the American Diabetes Association 2017 Guidelines and Joint National 
Commission 8 Guidelines, the goal for patients with diabetes is a systolic blood pressure is less 
than 140 and a diastolic blood pressure less than 90. However, after reviewing the literature, 
there is still some debate on the optimal blood pressure to minimize diabetic complications and 
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maintain quality of life. Furthermore, treatment of hypertension in patients with diabetes is also 
challenging due in part to conflicting evidence about appropriate drug regimens; combined with 
genetic, environmental, and psychosocial factors the struggle to control increases. The use of 
antihypertensive are reserved for patients with diabetes whose blood pressure remains elevated 
despite lifestyle modifications. Therefore, understanding the parameters for blood pressure 
control in patients with diabetes and how best to treat them will minimize the risk of vascular 
complications that can result in end organ damage.   
Case Report 
 A pleasant 60-year-old female in no acute distress was seen in clinic for management of 
her diabetes. She had a medical history of diabetes mellitus with lower extremity neuropathy, 
hypertension, hyperlipidemia, and a past family history of coronary artery disease (CAD) and 
colon cancer. She had a drug allergy to penicillin. Her home medication list consisted of daily 
Aspirin 81 mg, Atorvastatin 20 mg, Lisinopril 20 mg, Multivitamin, and Metformin 500 mg two 
times a day (BID). She denied history or current tobacco abuse or illicit drug use. She was a 
social drinker, but denied history of abuse. She had received her influenza and shingles 
vaccination. Her health maintenance screenings were up to date apart from a colonoscopy and 
DEXA scan.  
 In review of her systems, the patient denied any acute illness or changes to her health. 
Patientwas alert and able to answer questions appropriately. She denied fevers, chills, dizziness, 
or syncopal episodes. She denied respiratory alterations such as shortness of breath or dyspnea. 
She denied cough with or without sputum production. She denied cardiac dysfunction such as 
acute chest pain, cardiac palpitations or peripheral edema. Her bowel and bladder patterns 
remain unchanged. She denied heartburn or GI distress. She reported no abdominal pain or 
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discomfort. She denied altered musculoskeletal function or difficulty with mobility. She denied 
joint pain, back pain, or muscle pain. She reported good nutritional intake on a regular diet.  
 A thorough physical examination was conducted on the patient. Initially, her vital signs 
were as follows: blood pressure 148/98, heart rate 80, respiratory rate 20, and temperature 98.6 
degrees Fahrenheit. In general, the patient was a well-developed female in no acute distress with 
good mentation and affect. Her head was normocephalic, ears bilaterally set with no alterations 
in hearing, vision intact with good ocular movement noted, and her neck and throat were 
symmetrical with no thyromegaly present. An assessment of her lungs resulted in good 
inspiratory and expiratory capacity, symmetrical lung expansion, and no signs of respiratory 
distress. On auscultation her lungs were clear bilaterally within all lobes.  Her cardiac assessment 
revealed regular rhythm and rate with good S1 and S2 heard, no murmurs, clicks or rubs. 
Peripheral pulses were 2+ and palpable with signs of adequate circulation as evidenced by no 
peripheral edema. Abdomen was soft and nontender to palpation and active bowel sounds in all 
four quadrants. Skin was dry, but intact with no evidence of slow healing ulcers or wounds. 
Patient exhibited no difficulty with mobility or movement of all extremities. Microfilament 
testing revealed evidence of neuropathy on bilateral feet. Neurologically the patient had all 
cranial nerves II-XII intact.  
A crucial element of the patient’s assessment is to obtain laboratory tests that will aid the 
clinician in creating a treatment plan that is best suited for the patient. Laboratory testing 
required and completed was a basic metabolic panel, Hgb A1C, and lipid panel. A BMP will 
measure her electrolytes and renal function; which was found to be within defined limits apart 
from an increased glucose at 138 and decreased eGFR at 53. Obtaining an Hgb A1C is important 
to understand the patients average blood glucose levels in the last 3 months. Her Hgb A1C was 
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elevated at 7.8%, indicating an average blood glucose of 177 (Diabetes Care, 2008). Lastly, the 
patient requireed a cholesterol or lipid panel to identify her propensity for developing 
atherosclerosis leading to CVD. Her lipid panel revealed elevated triglycerides at 186 mg/dL and 
an elevated total cholesterol of 220 mg/dL.  
 Based on the medical history, physical examination, and review of laboratory results, the 
impression and plan for this patient should focus on lowering blood pressure, cholesterol, and 
blood sugars. Per the ADA 2017 Guidelines, the goals for this patient should include a BP less 
than 140/90, triglyceride level less than 150 with a total cholesterol level less than 199, and Hgb 
A1C less than 6.5.  However due to the family history of cardiovascular disease and her risk for 
developing kidney disease, consider a BP goal less than 130/80 (Boer, et al., 2017). Her plan 
would require an increase in Lisinopril to 40 mg daily, increase Atorvastatin to 40 mg daily, and 
increase Metformin to 1000 mg BID. In addition to pharmacological interventions, the patient 
requires education regarding management of diabetes. Currently the patient reported that her 
lifestyle includes limited physical exertion and irregular eating habits. Education about lifestyle 
modifications should include addition of daily exercise, maintaining a healthy BMI, and 
moderating nutritional intake.  
In addition to increasing her medication dosages and modifying her daily habits, the 
patient needs referrals to appropriate clinicians that can monitor her disease progression and 
prevent organ damage. Thus, scheduled appointments with a nephrologist and ophthalmologist 
are required. Plan to repeat labs in 3 months to monitor her lipid levels, electrolytes and kidney 
function, and Hgb A1C. In addition to ordering repeat laboratory testing and specialty referrals, 
the patient should be educated on checking her blood sugar levels and blood pressure daily to 
identify trends and treat accordingly.  
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Literature Review 
 Hypertension is common among patients with diabetes, with the prevalence depending on 
the type and duration of diabetes, age, sex, race/ethnicity, BMI, history of glycemic control, and 
the presence of kidney disease, among other factors (Boer, et al., 2017). The evidence suggests 
that more aggressive control of blood pressure is preferred in patients with diabetes than without 
to decrease the risk of atherosclerotic cardiovascular disease, microvascular and macro vascular 
complications. Initially and at every clinic visit, blood pressure readings need to be obtained to 
detect trends of elevated blood pressure. For a patient to be identified as having high blood 
pressure, they require an elevated reading on a separate day within one month of initial reading 
(Boer, et al., 2017). However, interpreting blood pressure readings and understanding the risks it 
can pose on the patient’s health is crucial. There is no exact blood pressure measurement in 
patients with diabetes that will prevent complications, however, several research studies have 
been conducted to determine the appropriate blood pressure levels to minimize health risks.  
 Per the American Diabetes Association 2017 Guidelines, the goal blood pressure is a 
systolic blood pressure less than 140 and a diastolic blood pressure less than 90 (Boer, et al., 
2017), which coincides with Joint National Committee 8 recommendations. In a non-
complicated patient with diabetes with minimal comorbidities and risk factors, this would be an 
ideal goal that could be obtained with lifestyle modifications. Often, this goal is set for adults 
aged 30-59 whose risks for developing complications is minimal. An online medical database 
known as Up to Date, which is beneficial in assisting healthcare professionals to obtain current 
evidence-based health information on various health topics recommends in all patients with 
diabetes a blood pressure less than 140/90 (Bakris, 2017). It is important to remember that early 
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identification and treatment of hypertension in patients with diabetes is required no matter their 
age to prevent micro or macro vascular complications. 
Lower blood pressure parameters are indicated for people who have renal or cardiac 
dysfunction. Per the National Kidney Foundation and the 2017 American Cardiology/American 
Heart Association hypertension guidelines, the recommended blood pressure should be less than 
130/80 mm Hg, with an optimal target below 120/80 mm Hg in people with diabetes (Konzem, 
Devore, & Bauer, 2002; Bakris, 2017). Hypertension is often present in patients with type 2 
diabetes that can lead to renal disease, which is suspected with the presence of micro and macro 
albumin in the urine.  The presence of micro albuminuria can result in accelerated renal 
dysfunction and eventual failure within the diabetic population. Therefore, based on the blood 
pressure recommendation above, to prevent the occurrence of renal complications in patients 
with diabetes, a lower blood pressure is indicated and should be obtained with pharmacologic 
therapy.  
As mentioned, a stricter blood pressure parameter is indicated to prevent cardiovascular 
complications. A meta-analysis was completed and found that a BP less than 130/80 resulted in 
less atherosclerotic cardiovascular disease (ASCVD) events, myocardial infarctions, and strokes 
(Franklin & Wong, 2017). Due to the results of the meta-analysis, they concluded all people with 
or without cardiovascular disease should aim for a BP less than 130/80.  However, the clinician 
must consider that blood pressure is multifactorial and lower measurements may result in 
additional adverse effects especially within the elderly population. Clinicians should aim for 
these measurements, but treatment in lowering should be conducted safely with consideration of 
the patient and their health needs.  
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It is safe to conclude that lower blood pressure greatly decreases complications in 
patients with diabetes, however can blood pressure less than 120/80 be more damaging than 
beneficial in patients with diabetes? Epidemiological evidence demonstrates that BP less than 
120/80 is associated with increased cardiovascular events and mortality in patients with diabetes 
(Arauz-Pacheco, Parrott, & Raskin, 2002). The ACCORD trial examined the effects of intensive 
blood pressure control less than 120/80 and concluded that there was no reduction in the rate of 
fatal and nonfatal major cardiovascular events (Cushman, et al., 2010). However, lower blood 
pressure did result in volume depletion leading to orthostatic changes, increased syncopal 
episodes, and kidney injuries due to lack of adequate perfusion. As many of the symptoms of 
volume depletion and hypoglycemia are similar, it can be challenging for the patient to 
understand the cause of their symptoms, resulting in greater caloric intake due to concern of 
hypoglycemia.  Therefore, treatment strategies to control blood pressure in patients with diabetes 
need to be monitored closely for the development of adverse effects that can worsen glycemic 
control.  
Treatment strategies to control blood pressure requires the use of antihypertensive 
medications known as angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor 
blockers (ARB), diuretics, calcium channel blockers, and beta adrenergic blockers. In choosing 
an antihypertensive agent, consider agents that will prevent mortality, prevent adverse 
cardiovascular events, and prevent the development and progression of renal disease (Bakris, 
2017). There can be adverse drug reactions associated with antihypertensive, therefore caution is 
warranted when prescribing these drugs and should be chosen based on an individual’s health 
history and risk factors.  
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 Initiating anti-hypertensive therapy on a person with diabetes begins with an ACE-
inhibitor. ACE-inhibitors block the conversion of angiotensin-I to angiotensin-II both 
systemically and locally in multiple tissues as well as plasma (Aronow et al., 2011). The result is 
relaxed blood vessels resulting in lower blood pressure and greater reabsorption of water by the 
kidneys. Its primary benefit is in the control of blood pressure in patients with diabetes is to 
prevent the progression on diabetic renal disease and reduction in CVD outcomes. In addition to 
efficacy, these agents have the additional advantage of being particularly well tolerated since 
they produce few idiosyncratic side effects and do not have the adverse effects on lipid and 
glucose metabolism seen with higher doses of diuretics or beta blockers (Townsend, 2017). 
Some adverse effects of this drug class are hypotension, reduction in GFR, hyperkalemia, 
anemia, angioedema, or cough being the most common. Overall, this drug class is well tolerated 
and used as first line treatment of HTN in patients with diabetes.  
 Another antihypertensive drug class that is arguably equal as a first line agent in lowering 
blood pressure are angiotensin II receptor blockers (ARB). This drug class plays a role in 
protecting the kidneys in type 2 diabetes mellitus, both in established diabetic nephropathy with 
proteinuria and in patients with micro albuminuria (Aronow et al, 2011).  This is the preferred 
initial drug class in patients with heart failure, hypertension, and diabetes per the ADA 2017 
guidelines as they are capable of reducing mortality. The adverse effects of this drug class are 
similar to ACEI such as angioedema, hypotension, and cough as the most common symptom.  
Both ACEI and ARBs effect the renin-angiotensin system, which controls blood pressure 
through management of blood volume and pressure (Singh, Mensah, & Bakris, 2010). Several 
studies have been conducted that found taking both an ACE-inhibitor and an ARB can lead to 
worse renal function resulting in development of diabetic nephropathy and chronic kidney 
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disease. The use of combined antihypertensive therapy is often needed to control blood pressure; 
however, it is not recommended that both an ACEI and an ARB be used together due to risk of 
CV events.  
 Diuretics are also utilized in the management and control of hypertension in patients with 
diabetes. Diuretics reduce total body sodium through their natriuretic action and have been 
shown to have vasodilatory effects (Arauz-Pacheco, Parrott, and Raskin, 2002). They primarily 
act on the renal system and can result in electrolyte imbalances that can alter cardiac function, 
resulting in the development of life threatening arrhythmias. They can also cause increased 
insulin sensitivity in patients with diabetes, resulting in better glycemic control. There use is 
indicated in people with CAD, congestive heart failure, diabetes, and hypertension. The use of 
diuretics as a monotherapy is acceptable in the treatment of heart failure, however for control of 
blood pressure in patients with diabetes combined therapy with a beta blocker is preferred, 
especially to halt or hinder deterioration of renal function.  
 The use of calcium channel blockers has gained favor in the treatment of HTN in patients 
with diabetes. They inhibit calcium influx through membrane-bound voltage dependent calcium 
channels, resulting in decreased intracellular calcium levels and vasodilation (Arauz-Pacheco, 
Parrott, and Raskin, 2002). They can be divided into 2 classes: dihydropyridine and 
nondihydropyridine. The dihydropyridine CCBs (e.g., nifedipine and amlodipine) are more 
selective in blocking L-type calcium channels in vascular smooth muscle cells, inducing vascular 
relaxation and reduced BP, compared to nondihydropyridine CCBs (e.g., diltiazem and 
verapamil) (Aksnes, Skarn & Kjeldson, 2018). They have a great impact on preventing 
cardiovascular events by altering lipid and carbohydrate metabolism. In one study, the use of 
CCB resulted in increased risk of diabetic nephropathy due to the increase in proteinuria. 
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Therefore, the recommendation is combining a CCB with an ACE inhibitor or an ARB to 
prevent renal dysfunction. Overall, CCBs are well tolerated and very effective in lowering BP, 
and are often needed to achieve a target value of BP in diabetic patients, especially in 
combination treatment (Aksnes, Skarn & Kjeldson, 2018).  
Beta adrenergic blockers, also known as beta-blockers, are another antihypertensive drug 
class that can be effective in hypertensive patients with diabetes. There use is not first line due to 
the risk of masking hypoglycemic symptoms and possibly exacerbating peripheral artery disease 
(Bakris, 2017). Therefore, these medications are to be avoided in patients with diabetes, 
especially those whom require insulin control as it can mask the symptoms of hypoglycemia 
leading to a diabetic coma. The use of medications within this drug class are prescribed when 
blood pressure is uncontrolled and are often used in combination with other agents. They have 
increased adverse effects with such as glucose intolerance resulting in slightly higher glycated 
hemoglobin concentrations (Marks, 1999). However, the benefits of these medications greatly 
outweigh the adverse effects, especially in management of cardiovascular disease. Beta blockers 
interfere with lipid metabolism and are associated with alteration of serum triglyceride and HDL-
cholesterol concentrations (Podrid, 2016), resulting in decreased development of arteriosclerosis 
within the diabetic population.  
 The use of combined antihypertensive therapy is often preferred in part because blood 
pressure is multifaceted and requires multiple interventions to control. The use of diuretics 
combined with beta-blockers has been shown to reduce diabetic nephropathy. The combination 
of ACE inhibitors with diuretics and calcium channel blockers can reduce blood pressure and 
urinary albumin levels compared to any medication alone (Arauz-Pacheco, Parrott, and Raskin, 
2002). There is no one medication used alone that will provide blood pressure stability within the 
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evidence-based parameters to minimize micro and macro vascular risks. However, if 
hypertension persists with monotherapy, then dual or combined therapy is recommended and 
even required in many patients with diabetes to control blood pressure. 
 Below is a helpful algorithm created by the American Diabetes Association Standards of 
Medical Care in Diabetes-2017 that can aid the clinician in choosing appropriate 
pharmacological interventions in people with diabetes.  
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Learning Points 
• The prevalence of hypertension and diabetes remains a growing problem in America and 
without early identification and treatment will result in the development of micro and macro 
vascular disease.  
• Per the American Diabetes Association 2017 Guidelines and Joint National Committee 
Guideline 8, the goal blood pressure in patients with diabetes is a systolic less than 140 and a 
diastolic less than 90.  
• In patients with additional comorbidities such as renal disease and cardiovascular disease, 
tighter blood pressure control is indicated. Therefore, the goal is for a systolic less than 130 
and a diastolic less than 80.  
• When initiating antihypertensive therapy, the use of an ACE inhibitor or an ARB is 
recommended as well as providing education on lifestyle modifications as control of blood 
pressure requires multiple interventions.  
• People with multiple comorbidities require use of an intense antihypertensive such as beta-
blockers and calcium channel blockers in combination with an ACEI or an ARB to prevent 
diabetic nephropathy.  
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